Epigenetic Age

Epigenetic clocks read biological age from DNA methylation patterns at thousands of CpG sites across the genome. The current generation (GrimAge, DunedinPACE, PhenoAge methylation) outperforms simpler blood-based composites at predicting all-cause mortality and morbidity, and they respond measurably to interventions over six to twelve month windows. Of every single-test longevity marker available today, this is the most validated.

Optimal range

Range varies by individual.

Test frequency

Once for an informed baseline. Repeat every six months during active intervention, then annually for long-term tracking. More frequent testing wastes money, the clocks move slowly and within-person noise dominates short intervals.

When to measure

Take a baseline once you have stable lifestyle habits, then re-measure at six to twelve months after a deliberate intervention (training block, weight loss, supplement protocol, medication change). Avoid sampling during acute illness, immediately after vaccination, or during an active inflammatory flare, methylation patterns shift transiently and can add or subtract apparent years from the result. Bundle with a comprehensive metabolic panel so any unusual reading can be cross-checked against routine bloodwork.

How to measure

Commercial epigenetic age tests use either saliva (TruDiagnostic TruAge, Elysium Index, MyDNAge) or a dried blood spot. Cost is $200–$500 per test; results return in three to six weeks. Methodologies vary; if you are tracking trends, stay with the same lab and the same clock version so the numbers are comparable. Most providers report multiple clocks per sample (GrimAge, DunedinPACE, PhenoAge methylation), which lets you triangulate.

Why this biomarker matters

Horvath's original 2013 clock established that DNA methylation tracks chronological age with surprising precision; the second-generation clocks (GrimAge, PhenoAge methylation) were trained directly against mortality and morbidity endpoints and predict them better than chronological age alone. A GrimAge five years above chronological age associates with roughly a 50 percent higher all-cause mortality hazard across the next decade in published cohorts. DunedinPACE measures the rate of aging rather than the cumulative deficit, expressing biological aging as a multiplier (1.0 = aging one year per calendar year, 1.2 = aging 20 percent faster than the reference cohort). Both GrimAge and DunedinPACE move in response to caloric restriction, structured exercise, and pharmacologic interventions in small but increasing numbers of trials. Evidence is early-stage; the clocks should be tracked as a trend, ideally against a stable baseline, not interpreted as precise predictions from a single sample.

The prime report

Weekly performance intelligence.

New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.